treatment-resistant depression

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.

Trump executive order accelerates psychedelic drug approvals from 6-10 months to 1-2 months, allocates $50M for research, benefiting biotech companies.

Psychedelic therapy advances as clinical treatment for depression and PTSD, with companies like Compass Pathways pursuing FDA approvals. The investment opportunity centers on $10,000-$20,000 treatment services rather than drugs.

AtaiBeckley will showcase its FDA-designated breakthrough therapy BPL-003 at Needham conferences in April, advancing toward Phase 3 trials in 2026.

Johnson & Johnson's SPRAVATO demonstrates sustained effectiveness for treatment-resistant depression in 570-patient European study, with benefits persisting 6 months post-treatment.

AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.

Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.